BrightSpring Health Services, Inc. Q3 FY2026 earnings call

• Financial Performance: Total revenue reached $4.2 billion (+26% YoY) and Adjusted EBITDA was $228 million (+42% YoY). EPS increased 80% YoY to $0.54. Cash flow from operations exceeded $200 million ($204 million).
• Strategic Focus: The company emphasizes long-term execution, operational efficiency, and accretive M&A within fragmented, high-demand markets like home health, hospice, and specialty pharmacy.
• Specialty Pharmacy Strengths: Launched seven LDDs in Q3 (19 YTD), supporting 162 total LDDs. Branded LDD performance is outpacing 2025 launch cohorts. Script growth in specialty was 29%, driven by branded LDDs, generics, and mid-teens growth in acute/chronic infusion.
• Home and Community Pharmacy Turnaround: Despite IRA headwinds (~$50M impact in Q3, ~$200M full-year estimate), underlying growth is improving. The segment is becoming a contributor to organic growth through technology investments and focus on attractive end-markets (hospice, ALF, behavioral).
• Provider Services Momentum: Home Health census grew ~58%, supported by de novo locations, MA relationships, and integration of Omedisys/LHC branches. Quality metrics are strong, with 96% of legacy branches rated 4-stars or better. Hospice and Rehab care show consistent quality and steady growth.
• Primary Care & ACO Integration: Selected as a provider for the new LEED ACO Medicare program starting January 2027. Primary care is viewed as a linchpin for integrated care, reducing hospitalizations by 50% in their model. Virtual primary care offerings are expanding.
• Operational Efficiency & AI: Significant investments in AI and technology are driving automation in documentation, medication review, HR, and employee efficiency. Corporate SG&A leverage is being maintained while investing in future growth.
• Capital Allocation: Leverage ratio reduced to 1.79x. Company generated $204 million in operating cash flow. Plan to discuss 2027 guidance in Q4, but anticipate 15-20% organic Adjusted EBITDA growth in 2027.

Pharmacy Solutions: Revenue was $3.7 billion (26% YoY growth), representing approximately 88% of total company revenue. Segment EBITDA was $202 million (43% YoY growth) with a margin of 5.4%. Key drivers included Specialty and Infusion revenue of $3.2 billion (34% YoY growth) driven by 29% script growth and new Low-Dose Drug (LDD) launches; Home and Community Pharmacy revenue declined 6% to $553 million due to ~$50 million in IRA impacts and voluntary customer exits.

Provider Services: Revenue was $481 million (31% YoY growth), representing approximately 12% of total company revenue. Segment EBITDA was $79 million (30% YoY growth) with a margin of 16.4%. Growth was driven by Home Health Care revenue of $288 million (50% YoY growth, including ~$76 million from Omedisys/LHC acquisitions), Rehab Care revenue of $82 million (8% YoY growth), and Personal Care revenue of $111 million (8% YoY growth).

• Full Year 2026 Revenue: Expected between $15.9 billion and $16.125 billion (23.2% - 24.9% growth over FY2025). This includes Pharmacy Solutions revenue of $14.0-$14.2 billion and Provider Services revenue of $1.9-$1.925 billion.
• Full Year 2026 Adjusted EBITDA: Expected between $850 million and $860 million (37.6% - 39.3% growth over FY2025). Includes ~$35 million contribution from Omedisys/LHC acquisitions.
• Full Year 2026 Cash Flow: Projected operating cash flow of at least $700 million (excluding Community Living impacts), with EBITDA to operating cash conversion of approximately 80%. Free cash flow after CapEx expected to exceed $600 million.
• 2027 Outlook: Management anticipates another positive year with at least 15-20% organic Adjusted EBITDA growth, built on a significantly larger 2026 base. Quarterly growth in H2 2027 is expected to be slightly higher than H1 due to seasonal patterns. Detailed 2027 guidance will be provided in the Q4 call.

• Regulatory Impact (IRA): The Inflation Reduction Act continues to negatively impact Home and Community Pharmacy revenue, with an estimated total annual impact of ~$200 million in 2026.
• Customer Exits: Voluntary exit from uneconomic customers has contributed to revenue declines in the Home and Community Pharmacy segment.
• Integration Risks: While Omedisys/LHC integration is proceeding as expected, any failure to realize synergies or operational issues in acquired entities could impact performance.
• Market Competition: The specialty pharmacy landscape is narrowing, with intense competition for LDD contracts and potential margin pressure if market dynamics shift.
• Execution Risk: Maintaining high double-digit growth rates across diverse service lines requires continuous operational excellence and successful capital deployment in M&A.

Q: Analyst asked about the drivers behind the 24% YoY increase in gross profit per script and the proportion of scripts coming from Home and Community Pharmacy.

A: CFO Jen Phipps explained that mix was the key driver, specifically higher growth in specialty/infusion scripts which carry higher GP per script compared to the average. She noted that the company focuses on absolute GP dollars and EBITDA growth rather than per-script metrics, as script mix is a byproduct of business activity. Regarding volume, she confirmed that a vast majority of scripts come from Home and Community Pharmacy, though specific percentages are not publicly disclosed.

Q: Analyst Charles Rhyee asked if the 29% specialty script growth was sustainable given the layering effect of new LDD launches and what the lead time is for winning new LDD contracts.

A: CEO Jon Rousseau stated that the growth rate is consistent with the company's track record over the past few years, driven by strategy, team, and quality. He noted that while 29% is strong, it is still lower than the 30% growth in the Provider segment. Regarding lead times, he indicated that engagements typically start at least a year in advance, varying by circumstance, suggesting that current wins will contribute to growth over the next year or so.

Q: Analyst A.J. Rice asked about the M&A pipeline, noting that deal sizes seem to be increasing, and whether the company sees more opportunities in Provider services versus Specialty Pharmacy.

A: Rousseau clarified that while they may lean into slightly larger transactions (EBITDA around $20M+), tuck-ins remain the mainstay. He emphasized that the company remains active and bullish on M&A volume compared to recent years but stays intentional. On sector balance, he stated they maintain a balanced approach, citing abundant opportunities in home health, hospice, rehab, and primary care, whereas the specialty drug space has very few large targets available.

Q: Analyst David Larsen asked about the new LEED ACO Medicare program, how BrightSpring differentiates itself, and when it might become profitable, especially regarding downside risk.

A: Rousseau highlighted that primary care is the 'linchpin' for integrated care, driving quality and value-based care opportunities. He noted that while they had some shared savings this year, they are evolving to be principals in these models. Crucially, he stated there is currently zero downside risk in their ACO activities, viewing them as pure upside opportunities with low risk. He projected that impactful economics from the LEED ACO ramp-up would likely materialize by 2028.

Q: Analyst Steven Baxter asked why commercial payer mix appears to be driving more revenue growth (45-50%) in specialty/infusion this year compared to last year (one-third), and how this affects margins.

A: CFO Jen Phipps attributed the shift primarily to the introduction of new branded LDDs, which have a mix of Medicare and commercial payers. Additionally, she noted that infusion growth is heavily tilted toward commercial payers. CEO Rousseau added that expanding into rare/orphan diseases outside oncology often involves younger patient populations, naturally skewing the mix toward commercial insurance, deepening partnerships in that sector.